Bioxytran, Inc. has announced that on January 10, 2025, they will release a press statement regarding a recent preprint on immune checkpoint inhibitors and the influence of galectin-3 on therapy resistance. Authored by Dr. Adesuyi Ajayi, Dr. David Platt, and Andrew Blumenthal, the research details the potential of galectin-3 modulation to enhance objective response rates and remission-free survival in oncology patients. The press release will be titled "Bioxytran’s Cancer Preprint Reveals Potential to Enhance Most Immunotherapy Drugs" and will be distributed through Globe Newswire.
Notable Names: - Dr. Adesuyi Ajayi (interim CMO) - Dr. David Platt (CEO) - Andrew Blumenthal